Kiniksa二季度ARCALYST销售强劲并再次上调2026年收入指引

Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026
Management View
- "Kiniksa is in a strong position more than halfway through 2026 as we continue to execute across our portfolio," said (CEO & Chairman of the Board Sanj Patel), adding, "We continue to make excellent progress with ARCALYST" and "have advanced the [ KPL-387 ] program into the pivotal stage with the initiation of the Phase III trial, which we have named PASTORALE."
- "Robust revenue growth of more than $29 million over the previous quarter drove sales of $243.6 million in the second quarter," said (CEO & Chairman of the Board Patel), and "we've raised our full year 2026 revenue guidance from $930 million to $945 million to between $980 million and $995 million."
- "The pivotal Phase III trial of KPL-387 in recurring pericarditis has now been initiated and is already enrolling and dosing patients," said (Executive VP & Chief Medical Officer John Paolini), describing Phase II dose-focusing data in which "median time to treatment response was 4 days" and "median time to CRP normalization was 8 days," supporting "the 300-milligram monthly dose being evaluated in the Phase III study PASTORALE."
- "ARCALYST revenue grew 55% year-over-year to $243.6 million in the second quarter," said (Executive VP & CFO Mark Ragosa), and "we ended the second quarter with a $525.9 million cash balance, representing approximately $58 million of net cash generation for the period."
Outlook
- "We've raised our full year 2026 revenue guidance... to between $980 million and $995 million," said (CEO & Chairman of the Board Patel), compared with Q1’s raised range of "$930 million to $945 million" (also attributed to (CEO & Chairman of the Board Patel) in the prior call).
- "We anticipate a potential commercial launch of [ KPL-387 ] in the 2028 and 2029 time frame," said (CEO & Chairman of the Board Patel), and (Executive VP & Chief Medical Officer Paolini) reiterated, "our goal is to bring this potential new additional treatment option to patients in the 2028 to 2029 time frame."
- No EPS guidance was provided in the transcript, and the estimates JSON was not used due to format mismatch with the requested validation rules.
Financial Results
- "ARCALYST revenue grew 55% year-over-year to $243.6 million," said (Executive VP & CFO Ragosa), and "together, these factors contributed to year-over-year increases in operating income and net income, which were $27.2 million and $25.4 million, respectively."
- "ARCALYST's collaboration profit grew faster than sales on a year-over-year basis, increasing 68% to $176.1 million," said (Executive VP & CFO Ragosa).
- "Year-to-date. gross to net is 7.2%, down from 8.6% in the first quarter," said (Executive VP & CFO Ragosa), adding that the "main driver" was "lower co-pay due to the changes that we made to our support program at the beginning of the year."
Q&A
- Nicholas Lorusso, TD Cowen, Research Division: "what drove this growth specifically in Q2?"; (Executive VP, COO & Principal Operating Officer Ross Moat) answered, "we've seen a substantial uplift in the number of both new prescribers and new repeat prescribers," citing "more than 450 new prescribers" and "more than 150 new repeat prescribers" and pointing to investments in "AI and machine learning" and early signs from the DTC campaign.
- Eva Fortea-Verdejo, Wells Fargo Securities, LLC, Research Division: "Is there a specific patient profile" and "can you comment on the gross to net"; (Executive VP, COO & Principal Operating Officer Moat) said, "We haven't really seen any changes in the actual patient profiles," while (Executive VP & CFO Ragosa) said, "gross to net does move lower sequentially in the second quarter" and described the quarterly pattern into Q4.
- Geoffrey Meacham, Citigroup Inc., Research Division: "anything you guys have embedded in the Phase III" and demand from first recurrence; (Executive VP & Chief Medical Officer Paolini) said Phase III reflects "rapid onset of action" and "durable efficacy," while (Executive VP, COO & Principal Operating Officer Moat) said "about 20% of the ARCALYST prescriptions in Q2" were in first recurrence and "that's been growing over time."
- Anupam Rama, JPMorgan Chase & Co, Research Division: time-to-response vs RHAPSODY and monthly regimen; (Executive VP & Chief Medical Officer Paolini) said, "we would concur" results are "consistent" with prior trials, and (Executive VP, COO & Principal Operating Officer Moat) cited market research with "around 75% of patients" preferring the target profile and "around 92% of health care professionals" indicating a high likelihood to prescribe.
- Kyuwon Choi, Goldman Sachs Group, Inc., Research Division: salesforce headcount and transition study; (CEO & Chairman of the Board Patel) said, "we're always looking at our sales force analytics" and "we continue to leverage the AI and machine learning," while (Executive VP & Chief Medical Officer Paolini) said the transition study is meant "to provide supplemental information for the label" for switching from "NSAIDs and colchicine or corticosteroids or IL-1 pathway inhibitors."
- David Nierengarten, Wedbush Securities Inc., Research Division: Phase II follow-up and recurrences; (Executive VP & Chief Medical Officer Paolini) said the readout was "an interval analysis" and "the disclosure is limited," adding only that the monthly-dose effect was "robust" and "the 300-milligram biweekly dose level... did not provide incremental benefit."
Sentiment Analysis
- Analysts’ tone was positive and congratulatory, including "Congrats on the very strong quarter" (Nicholas Lorusso, TD Cowen, Research Division) and "Congrats on the quarter" (Eva Fortea-Verdejo, Wells Fargo Securities, LLC, Research Division), with probing focused on sustainability of ARCALYST growth and KPL-387 differentiation.
- Management’s tone was confident in commercial execution and pipeline timing, including "Kiniksa is in a strong position" (CEO & Chairman of the Board Patel) and "we are pleased with the Q2 performance" (Executive VP, COO & Principal Operating Officer Moat), while becoming more guarded on selective clinical details: "the disclosure is limited" (Executive VP & Chief Medical Officer Paolini).
- Versus Q1, management’s posture shifted from planning ("expect to start the Phase III portion... by the end of this year," said (CEO & Chairman of the Board Patel) previously) to execution ("this Phase III study has already started," said (CEO & Chairman of the Board Patel) in Q2).
Quarter-over-quarter Comparison
- Revenue guidance was raised again: Q1 guidance increase to "$930 million to $945 million" (CEO & Chairman of the Board Patel, prior call) followed by Q2’s increase to "between $980 million and $995 million" (CEO & Chairman of the Board Patel).
- KPL-387 advanced from Q1 expectations ("Data... on track for the second half of this year" and "expect to start the Phase III portion... by the end of this year," said (CEO & Chairman of the Board Patel) previously) to Q2’s dose selection and trial start: "moving forward with the target profile of a monthly dose" and "is now enrolling and dosing patients" (CEO & Chairman of the Board Patel).
- Commercial metrics broadened: Q1 cited "approximately 400 new prescribers" and "more than 4,550" total prescribers (Executive VP, COO & Principal Operating Officer Moat, prior call), while Q2 cited "approximately 450" new prescribers in-quarter and "more than 5,000" total prescribers (Executive VP, COO & Principal Operating Officer Moat).
Risks and Concerns
- Commercial expansion continues to hinge on diagnosis and awareness dynamics: "the misdiagnosis and underdiagnosis rate is pretty substantial" (Executive VP, COO & Principal Operating Officer Moat).
- Net pricing seasonality and program changes remain a variable: "gross net historically has been highest in the first quarter, lower in Q2 and Q3" (Executive VP & CFO Ragosa).
- Clinical disclosure limitations were explicit on KPL-387 follow-up/recurrences: "the disclosure is limited" (Executive VP & Chief Medical Officer Paolini).
Final Takeaway
Management framed Q2 around accelerating ARCALYST commercial momentum, a second consecutive full-year 2026 revenue guidance increase to $980 million-$995 million, and a step-change in pipeline execution with KPL-387 moving from dose-focusing results to active Phase III enrollment in PASTORALE, while emphasizing disciplined commercial investment, gross-to-net seasonality, and limited additional disclosure on the interim Phase II/III analysis beyond supporting the 300-mg monthly dose selection.
Read the full Earnings Call Transcript